Hernandez, Carolina Dagli 
; Borges, Jéssica Bassani ; Marçal, Elisangela da Silva Rodrigues; Freitas, Renata Caroline Costa de ; Mori, Augusto Akira ; Gonçalves, Rodrigo Marques; Faludi, André Arpad ; Oliveira, Victor Fernandes de ; Ferreira, Glaucio Monteiro ; Bastos, Gisele Medeiros ; Zhou, Yitian ; Lauschke, Volker Martin ; Cerda, Alvaro ; Hirata, Mario Hiroyuki ; Hirata, Rosario Dominguez Crespo
Source: Pharmaceutics. Unidade: FCF
Subjects: HIPERCOLESTEROLEMIA, ESTATINAS, VARIAÇÃO GENÉTICA, FARMACOGENÉTICA, MEDICAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
HERNANDEZ, Carolina Dagli et al. Genetic variant ABCC1 rs45511401 is Associated with increased response to statins in patients with familial hypercholesterolemia. Pharmaceutics, v. 14, p. 1-20 art. 944, 2022Tradução . . Disponível em: https://doi.org/10.3390/pharmaceutics14050944. Acesso em: 14 nov. 2024.APA
Hernandez, C. D., Borges, J. B., Marçal, E. da S. R., Freitas, R. C. C. de, Mori, A. A., Gonçalves, R. M., et al. (2022). Genetic variant ABCC1 rs45511401 is Associated with increased response to statins in patients with familial hypercholesterolemia. Pharmaceutics, 14, 1-20 art. 944. doi:10.3390/pharmaceutics14050944NLM
Hernandez CD, Borges JB, Marçal E da SR, Freitas RCC de, Mori AA, Gonçalves RM, Faludi AA, Oliveira VF de, Ferreira GM, Bastos GM, Zhou Y, Lauschke VM, Cerda A, Hirata MH, Hirata RDC. Genetic variant ABCC1 rs45511401 is Associated with increased response to statins in patients with familial hypercholesterolemia [Internet]. Pharmaceutics. 2022 ; 14 1-20 art. 944.[citado 2024 nov. 14 ] Available from: https://doi.org/10.3390/pharmaceutics14050944Vancouver
Hernandez CD, Borges JB, Marçal E da SR, Freitas RCC de, Mori AA, Gonçalves RM, Faludi AA, Oliveira VF de, Ferreira GM, Bastos GM, Zhou Y, Lauschke VM, Cerda A, Hirata MH, Hirata RDC. Genetic variant ABCC1 rs45511401 is Associated with increased response to statins in patients with familial hypercholesterolemia [Internet]. Pharmaceutics. 2022 ; 14 1-20 art. 944.[citado 2024 nov. 14 ] Available from: https://doi.org/10.3390/pharmaceutics14050944
